Astellas Pharma Archives - DelveInsight

Astellas Pharma

Interstitial-Cystitis-market-size-share-pipeline-analysis
Interstitial Cystitis: A big opportunities for emerging drugs

Interstitial Cystitis market comprises robust pipeline therapies in late and mid-stage development, which are expected to be launched shortly, such as KRP-116D (Kyorin Pharmaceutical), Certolizuma...


Acute Kidney Injury Pipeline
Watch Out for the Most Promising Therapies in the Pipeline in Acute Kidney Injury Market

The Acute Kidney Injury Therapies in the pipeline anticipated to launch in the next decade shall spur the AKI Market growth forward. Acute Kidney Injury (AKI) is defined as a sudden advent of ...


Top-cancers-in-the-world
Top 5 Cancers Creating Major Challenge To The Global Healthcare System

Over the past few decades Cancer has emerged as a major public health concern worldwide. Cancer is the second leading cause of deaths that takes place worldwide. Every sixth death is due to cancer...


pharma-news
Alnylam’s lumasiran results; AZ’s oncology drug; Astellas Roxadustat; Evotec’s partnership with ABL

Alnylam Pharmaceuticals has released the Phase III results of the clinical trial ILLUMINATE-A evaluating lumasiran for Primary Hyperoxaluria Type 1 Primary Hyperoxaluria Type 1 (PH1) is a rare ...


Prostate Cancer Market
Prostate Cancer Market Experiences an Influx of the Pharma Players Veering the Market Ahead

Prostate Cancer Market Size is Expected to Increase with a CAGR of 8.1% in the 7MM for the study period of 2017-30 owing to rich Pipeline, Increasing Awareness and Better Treatment Options. A m...


Acute Kidney Injury Market
Emerging Therapies that can significantly impact the Acute Kidney Injury Market

As per DelveInsight, Acute Kidney Injury Market Size in the 7 MM was observed to be USD 4,082.95 Million in 2017, which is expected to increase by 2030 significantly. Acute Kidney Injury (ARI...


Reblozyl under FDA review; Audentes buyout & Tecentriq’s new approval
Reblozyl under FDA review; Audentes buyout & Tecentriq’s new approval

Bristol-Meyers Squibb and Acceleron Pharma have announced that US FDA committee will review BMS’s supplemental Biologics License Application (sBLA) for its Reblozyl in MDS. Reblozyl ((luspater...


Pharma Business news
Osivax raises USD 9M; Smyraf launched; Revolution secures USD 100M

Osivax raises USD 9 M to boost its universal flu vaccine approach France based biotech startup company Osivax, has secured USD 9 million in Series A financing. A Belgian-based firm Noshaq alon...


Cholera vaccine delivered; Rice-inspired breakthroughs; International partnerships

Cholera vaccine delivered through a cup of rice water Vaccinations against prevalent pathogens could be ingested as oral or inhaled as nasal vaccines, this is due to the development of non-invasiv...


FDA
Copiktra receives approval; Lilly wins approval; Eisai’s Fycompa; Astellas’ Roxadustat; Janssen’s...

SNAPSHOTS: Copiktra receives FDA approval for CLL and FL, Relief for tazemetostat developers after FDA lifted partial clinical hold, Conference highlights from 19th WCLC The United States Food and...


Editor's Pick
Commercial Roadmap for the Launch: What can Biopharmaceuticals do to Increase...

The Pharma and Biotech Healthcare market has been an ever-changing industry in terms of...

Emerging Market for Organ on a Chip

The organ on a chip is a microfluidic culture device that recapitulates the complicated...

Global Top Players in Intraocular Lens (IOL) Market

 An Intraocular Lens implant is a synthetic, artificial lens placed inside the eye...

Investigating the Pipeline for Ankylosing Spondylitis Treatment Landscape

Ankylosing Spondylitis is a form of arthritis that primarily affects the spine. It caus...

LAG 3: A Promising Next Generation Cancer Immunotherapy

Immunotherapy also called biologic therapy, is a type of cancer treatment that boosts t...

ASCO Conference 2022
ASCO Conference 2022

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.